CFA
KPTI icon

CT Financial Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

CT Financial Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$6.42K Hold
33
– – ﹤0.01% 487
2016
Q4 		$4.7K Hold
33
– – ﹤0.01% 507
2016
Q3 		$4.87K Hold
33
– – ﹤0.01% 504
2016
Q2 		$3.35K Hold
33
– – ﹤0.01% 534
2016
Q1 		$4.46K Buy
33
+20
+154% +$2.21K ﹤0.01% 517
2015
Q4 		$2.65K Buy
+13
New +$2.81K ﹤0.01% 553
2015
Q3 		– Sell
-7
Closed -$2.72K – 657
2015
Q2 		$2.72K Hold
7
– – ﹤0.01% 559
2015
Q1 		$3.06K Hold
7
– – ﹤0.01% 550
2014
Q4 		$3.74K Buy
+7
New +$3.98K ﹤0.01% 447
2014
Q1 		$3.06K Buy
+7
New +$3.55K ﹤0.01% 550

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

CT Financial Advisors's KPTI Position: Q1 2017 in Review

CT Financial Advisors held its Karyopharm Therapeutics (KPTI) position steady in Q1 2017 at 33 shares worth $6.42K. The position accounts for ﹤0.01% of the portfolio, ranked #487.

CT Financial Advisors first reported a position in KPTI in Q1 2014 and has held it in 10 quarters since. 80 funds tracked by Wall St. Rank hold KPTI as of Q1 2017.

  • CT Financial Advisors held 33 shares of Karyopharm Therapeutics worth $6.42K as of Q1 2017.
  • CT Financial Advisors left its Karyopharm Therapeutics share count unchanged in Q1 2017.
  • Karyopharm Therapeutics made up ﹤0.01% of CT Financial Advisors's portfolio in Q1 2017, its #487 holding.
  • CT Financial Advisors first reported a position in Karyopharm Therapeutics in Q1 2014 and has held it in 10 quarters since.
  • 80 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.